Oslo, Norway, May 5, 2022 - The Board of Directors of Nykode Therapeutics AS
(Euronext Growth (Oslo): NYKD), a clinical-stage biopharmaceutical company
dedicated to the discovery and development of vaccines and novel
immunotherapies, hereby calls for the Annual General Meeting to be held at
meeting room FORUM - Building H, Floor 0 in Gaustadalléen 21, Oslo, Norway at
10:00 CET on May 12, 2022.
All documents regarding the Annual General Meeting are available at the
For further information, please see the Company's website or contact CFO Harald
Gurvin. Please see below for contact details.
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of vaccines and novel immunotherapies for the
treatment of cancer and infectious diseases. Nykode's modular vaccine technology
specifically targets antigens to Antigen Presenting Cells, which are essential
for inducing rapid, strong and long-lasting antigen specific immune responses
and eliciting efficacious clinical responses.
Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of human papilloma virus 16 induced malignancies which is in Phase 2
for the treatment of cervical cancer